Skip to content

T Regulatory Cells IN LUPUS NEPHRITIS

T Regulatory Cells in Lupus Nephritis

Status
Not yet recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT06428539
Enrollment
65
Registered
2024-05-24
Start date
2024-07-01
Completion date
2025-08-01
Last updated
2024-05-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Lupus Nephritis

Brief summary

* To study the role FoxP3-positive T regulatory cells in the pathogenesis of Lupus Nephritis, and determine the factors associated with levels of T regs . * To compare the functional capacity of T regs in LN and in normal individuals.

Detailed description

Lupus Nephritis (LN) encompasses a group of glomerulonephrites, that occur in association with systemic lupus erythematosus (SLE). The mainstream theory that it is an immune disease resulting from loss of immune tolerance against body cells. The regulatory T cells (T regs ) are a subpopulation of immune cells that maintain tolerance to self-antigens and suppress autoimmune diseases. The main marker of Tregs is FoxP3 (forkhead box protein 3) positivity. Moreover, It has been suggested that functional capacity of Tregs is also compromised in autoimmune diseases. Studying the role of T regs in LN is a promising field that can help tailor current immune therapy and develop new treatment strategies.

Interventions

DIAGNOSTIC_TESTT-reg cells

laboratory test

Sponsors

Assiut University
Lead SponsorOTHER

Study design

Observational model
CASE_CONTROL
Time perspective
CROSS_SECTIONAL

Eligibility

Sex/Gender
ALL
Age
18 Years to 85 Years
Healthy volunteers
Yes

Inclusion criteria

adults both genders clinical diagnosis of lupus nephritis

Exclusion criteria

patients diagnosed with other renal pathologies, e.g. diabetic kidney disease

Design outcomes

Primary

MeasureTime frameDescription
FoxP3 between groupsbaselinemean difference of FoxP3 between groups.
Association of FoxP3 and activity indexbaselinecorrelation between level of FoxP3 and activity index in the group with active LN.
Tregs in normal and lupus participantsbaselinemean difference of suppression capacity of Tregs between normal participants and patients with active LN.

Contacts

Primary ContactMohamed AH Hussein
mohammedaggag30@gmail.com+966554599271

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026